Global Pediatric Clinical Trials Market 2019-2024 – Phase II Segment Expected to Hold the Largest Market Share During the Forecast Period – ResearchAndMarkets.com
April 30, 2019DUBLIN–(BUSINESS WIRE)–The “Pediatric
Clinical Trials Market – Growth, Trends, and Forecast (2019-2024)”
report has been added to ResearchAndMarkets.com’s
offering.
The major factors for the growth of the pediatric clinical trials market
include the rising awareness about pediatric medicine, shifting in-house
clinical trials to CROs, and increasing burden of pediatric diseases,
such as diabetes. In the coming years, with the increasing importance of
pediatric medicine, the market for pediatric clinical trials is expected
to record steady growth.
Key Market Trends
Phase II Segment under Phase-wise Segmentation is expected to hold
the Largest Market Share during the Forecast Period
Phase II is the step after Phase I for any biopharmaceutical company to
proceed where clinical efficacy or biological activity (‘proof of
concept’ studies) and optimum dose to show biological activity with
minimal side-effects (definite dose-finding’ studies) are performed in
100-300 patients with the specific disease. The time period is several
months to two years in most scenarios. The success rate in this phase
drops down sharply, and as per the US FDA, the successful trials moving
forward are around 33%.
As per clinicaltrials.gov, nearly 5,849 studies are currently in process
2019 with active study undergoing. Owing to high uncertainty and the
complex procedure of data collection, analysis, and representation as
per government protocols, the pharmaceutical companies generally
outsource the clinical trials to the clinical research organizations
(CROs) with expertise in various protocols/guidelines laid down by
governments across the globe.
The rising number of collaborations of companies with hospital chains
and CROs with a focus on niche therapeutic segments act as the major
driving factors for the success and approval of candidates in this
phase. The emerging markets are a rising source of CROs and diversified
patient pool for the growth of success rate in phase II. Thus, owing to
all the above-mentioned factors, the market is expected to witness high
growth over the forecast period.
North America is expected to account for the Largest Market Share in
the Global Market
North America is found to hold a significant share for the pediatric
clinical trials market and is expected to show a similar trend over the
forecast period. The pediatric clinical trials scenario in the United
States has been fluctuating since 2005. The number of clinical trials
conducted on the pediatric population in the United States has been
increasing since 2005-2009. However, from 2009-2011, almost an equal
number of pediatric clinical trials were performed in the United States.
According to ClinicalTrials.gov, in 2019, more than 3,363 pediatric
research procedures were conducted in the United States, which
represented a large proportion of the overall global count of pediatric
research procedures. The high number of trials and high cost per
procedure and patient have largely contributed to the market in the
United States. This has made the US pediatric clinical trials market the
largest in the world.
The population of children in the United States is more than a quarter
of the total population, but the pediatric clinical trials performed are
ten times lesser than the non-pediatric ones. This is mainly because of
ethical issues related to pediatric research and the complexity
involved. Another major factor restraining the market is the relatively
small target population for the end product.
Competitive Landscape
The market studied is consolidated, owing to the presence of a few key
players in the market. Some of the market players are Bristol – Myers
Squibb, Charles River Laboratories International Inc., Covance Inc.,
ICON plc, IQVIA, Novartis AG, Pfizer, Inc., Pharmaceutical Product
Development, LLC, and Syneos Health Inc.
Key Topics Covered
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Awareness about Pediatric Medicine
4.2.2 Shifting In-house Clinical Trials to CROs
4.2.3 Increasing Burden of Pediatric Diseases, such as Diabetes
4.3 Market Restraints
4.3.1 Ethical Issues in Pediatric Research
4.3.2 Small Size of Study Population
4.4 Porter’s Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Phase
5.1.1 Phase I
5.1.2 Phase II
5.1.3 Phase III
5.1.4 Phase IV
5.2 By Study Design
5.2.1 Treatment Studies
5.2.1.1 Randomized Control Trial
5.2.1.2 Adaptive Clinical Trial
5.2.1.3 Non-randomized Control Trial
5.2.2 Observational Studies
5.2.2.1 Cohort Study
5.2.2.2 Case-Control Study
5.2.2.3 Cross-Sectional Study
5.2.2.4 Ecological Study
5.3 Geography
5.3.1 North America
5.3.2 Europe
5.3.3 Asia-Pacific
5.3.4 Middle East & Africa
5.3.5 South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bristol-Myers Squibb Company
6.1.2 Charles River Laboratories International Inc.
6.1.3 Covance Inc.
6.1.4 GlaxoSmithKline PLC
6.1.5 ICON PLC
6.1.6 IQVIA
6.1.7 Novartis AG
6.1.8 Pfizer Inc.
6.1.9 Pharmaceutical Product Development LLC
6.1.10 Syneos Health Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/yd67tq
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Clinical
Trials, Pediatrics